Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579759 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
A Phase 3 study, sponsored by Pharnext S.C.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 323
- Enrollment target
NCT02579759 is a Phase 3 study that has completed, run by Pharnext S.C.A.. The registered enrollment target is 323 participants.
The verdict
NCT02579759, a Phase 3 study, has completed, sponsored by Pharnext S.C.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 323 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.
Interventions
- DRUG placebo
- DRUG PXT3003 dose 1
- DRUG PXT3003 dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579759
The ClinicalTrials.gov registry entry for NCT02579759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharnext S.C.A., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02579759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02579759 about?
NCT02579759 is a clinical study titled "Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)". The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.
What is the current status of trial NCT02579759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 323 participants. The study started on 2015-12. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02579759?
The interventions under investigation include: placebo (DRUG), PXT3003 dose 1 (DRUG), PXT3003 dose 2 (DRUG).
Who is sponsoring clinical trial NCT02579759?
This trial is sponsored by Pharnext S.C.A., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.